Octagam 10gm/200ml Inj, 1 Vial

• Live virus vaccines (e.g., measles, mumps, rubella, varicella): IVIG can interfere with the immune response to live attenuated virus vaccines. Vaccination should be deferred for at least 3 months, and up to 1 year, after IVIG administration depending on the vaccine and IVIG dose.
• Loop diuretics (e.g., furosemide): Increased risk of acute renal dysfunction, especially in patients with pre-existing renal impairment or risk factors.

• Headache
• Fever
• Chills
• Nausea
• Vomiting
• Rash
• Hives
• Dyspnea
• Wheezing
• Chest tightness
• Back pain
• Muscle cramps
• Dizziness
• Fatigue
• Signs of thrombosis (e.g., pain, swelling, warmth, discoloration of an extremity; sudden chest pain, shortness of breath, slurred speech, weakness on one side of the body)
• Signs of renal dysfunction (e.g., decreased urine output, swelling in legs/feet, fatigue)
• Signs of aseptic meningitis (e.g., severe headache, neck stiffness, photophobia, fever, nausea, vomiting)

Immune globulins cross the placenta, particularly in the third trimester. While animal reproduction studies have not been conducted, clinical experience with IVIG in pregnant women has not shown evidence of adverse effects on the fetus. It is often used in pregnant women for specific indications (e.g., ITP, recurrent pregnancy loss). Use only if clearly needed.

Immune globulins are naturally present in human milk. Exogenous immune globulin is unlikely to be absorbed systemically by the infant. Considered compatible with breastfeeding.

Dosing is weight-based and indication-specific. Safety and efficacy have been established for various pediatric indications. Close monitoring for infusion-related reactions and renal function is important, especially in neonates and infants.

Elderly patients (age >65) are at increased risk for acute renal dysfunction and thrombotic events. Use with caution, ensure adequate hydration, consider lower infusion rates, and monitor renal function and signs of thrombosis closely. Pre-existing conditions (e.g., diabetes, cardiovascular disease) increase risk.

• Always ensure adequate hydration before, during, and after IVIG infusion to minimize the risk of renal dysfunction and thrombosis.
• Infuse at the slowest practicable rate, especially for the first infusion, and for patients at high risk of adverse reactions (e.g., elderly, renal impairment, cardiovascular disease). The rate can be gradually increased if tolerated.
• Pre-medication (e.g., acetaminophen, antihistamines, corticosteroids) may be used to mitigate infusion-related reactions, especially in patients with a history of such reactions or those receiving their first infusion.
• Patients with IgA deficiency who have antibodies to IgA are at increased risk of severe allergic or anaphylactic reactions. Octagam contains trace amounts of IgA. Screen for IgA deficiency prior to first infusion.
• Monitor for signs of aseptic meningitis syndrome (AMS), which can occur hours to days after IVIG infusion. Symptoms include severe headache, neck stiffness, photophobia, nausea, and vomiting. It is usually self-limiting.
• Thrombotic events, including stroke, myocardial infarction, DVT, and PE, can occur. Be vigilant for symptoms, especially in high-risk patients.
• Acute renal dysfunction is a serious potential adverse effect. Monitor renal function and urine output, especially in at-risk populations. Avoid sucrose-containing IVIG formulations in patients at risk for renal failure.

• Other Immune Globulin Intravenous (IVIG) brands (e.g., Gammagard, Privigen, Flebogamma, Gamunex-C, Asceniv, Panzyga)
• Subcutaneous Immune Globulin (SCIG) for chronic immunodeficiency (e.g., Hizentra, Cuvitru, Xembify, HyQvia)
• Corticosteroids (for autoimmune conditions like ITP, CIDP)
• Immunosuppressants (e.g., azathioprine, mycophenolate mofetil, cyclophosphamide, rituximab for autoimmune conditions)
• Plasma exchange (for acute severe autoimmune conditions)